Comparative Pharmacology
Head-to-head clinical analysis: FASENRA versus SAPHNELO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FASENRA versus SAPHNELO.
FASENRA vs SAPHNELO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benralizumab is a humanized afucosylated monoclonal antibody that binds to the alpha subunit of the interleukin-5 receptor (IL-5Rα) expressed on eosinophils and basophils. This binding inhibits IL-5-mediated signaling and induces antibody-dependent cell-mediated cytotoxicity (ADCC), resulting in rapid and near-complete depletion of eosinophils from blood and tissues.
SAPHNELO (anifrolumab) is a human monoclonal antibody that binds to the type I interferon (IFN) receptor subunit 1 (IFNAR1), blocking the activity of all type I IFNs (including IFN-α, IFN-β, and IFN-κ). This inhibition reduces the downstream signaling and expression of interferon-stimulated genes, thereby decreasing inflammation and immune activation associated with systemic lupus erythematosus.
30 mg subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks thereafter.
300 mg intravenously every 4 weeks, administered as a 1-hour infusion.
None Documented
None Documented
Terminal half-life approximately 25 days (range 24–27 days), supporting every-4-week subcutaneous dosing.
Terminal elimination half-life is approximately 27.4 days (range 17–34 days), supporting every-4-week dosing. Steady-state is reached by 10–12 weeks.
Degraded into small peptides and amino acids via general protein catabolism; no significant renal or biliary/fecal excretion of intact drug.
SAPHNELO (anifrolumab) is primarily eliminated via intracellular catabolism; no specific renal or biliary excretion data. As a monoclonal antibody, it is not excreted renally or hepatically.
Category C
Category C
Monoclonal Antibody, Anti-Interleukin-5 Receptor
Monoclonal Antibody